McKesson Corporation (MCK) valuation
McKesson P/E ratio history
McKesson trades at 26.7 times its earnings over the last twelve months and 21.5 times the earnings analysts expect over the next twelve. At its last 7 fiscal year ends its P/E ranged from 6.4 (year to Mar 2017) to 42.3 (year to Mar 2022), with a median of 24.0.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Mar 31, 2026 | $865.36 | $38.38 | 22.6 | 20.1 |
| Mar 31, 2025 | $672.99 | $25.72 | 26.2 | 19.4 |
| Mar 31, 2024 | $536.85 | $22.39 | 24.0 | 17.8 |
| Mar 31, 2023 | $356.05 | $25.03 | 14.2 | 13.5 |
| Mar 31, 2022 | $306.13 | $7.23 | 42.3 | 13.1 |
| Mar 31, 2021 | $195.04 | -$28.62 | n/m | — |
| Mar 31, 2020 | $135.26 | $5.13 | 26.4 | — |
| Mar 31, 2019 | $117.06 | — | n/m | — |
| Mar 31, 2018 | $140.87 | — | n/m | — |
| Mar 31, 2017 | $148.26 | $23.33 | 6.4 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
McKesson valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| McKessonMCK | $120B | 26.7 | 21.5 | 0.3 |
| CVS HealthCVS | $115B | 23.8 | 10.9 | 0.3 |
| HCA HealthcareHCA | $102B | 15.7 | 15.3 | 1.3 |
| Elevance HealthELV | $91.2B | 17.8 | 14.0 | 0.5 |
| CignaCI | $78.9B | 12.3 | 9.3 | 0.3 |
| Cardinal HealthCAH | $58.7B | 34.6 | — | 0.2 |
| Veeva SystemsVEEV | $50.8B | 51.2 | 32.1 | 14.7 |
| HumanaHUM | $49.8B | 39.1 | 31.6 | 0.3 |
| UnitedHealth GroupUNH | $370B | 26.1 | 18.0 | 0.8 |
| Peer median | 25.0 | 15.3 | 0.4 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: MCK financials · MCK returns
No forecast, no recommendation. This page describes McKesson Corporation from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.